Curis Inc (CRIS)

NASDAQ
0.818
+0.041(+5.26%)
  • Volume:
    192,074
  • Day's Range:
    0.770 - 0.835
  • 52 wk Range:
    0.470 - 1.770

CRIS Overview

Prev. Close
0.777
Day's Range
0.77-0.835
Revenue
10.4M
Open
0.77
52 wk Range
0.47-1.77
EPS
-0.551
Volume
192,074
Market Cap
78.94M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
390,343
P/E Ratio
-1.53
Beta
2.94
1-Year Change
1.66%
Shares Outstanding
96,617,898
Next Earnings Date
Aug 03, 2023
What is your sentiment on Curis?
or
Market is currently closed. Voting is open during market hours.

Curis Inc Company Profile

Curis Inc Company Profile

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Read More

Analyst Price Target

Average6.750 (+723.171% Upside)
High10.000
Low3.000
Price0.820
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyNeutralStrong Sell
  • best idea in medical world....
    0
    • i bought .good company
      0
      • I bought.
        0
        • What do you think the price?
          0
        • Will be
          0
        • Well, the TP is very steep (7ish). Starting from -33% should position me in a positive way. Or, at least, I hope so! Cheers.
          0
      • This is like BTX, from 9-81 then went down
        2
        • Why is it to the moon today🤔
          1
          • where do you see curis in 6mths?
            0
            • Holy cow!! I bought a thousand of this at .68 in March on robinhood and forgot about it. What a nice surprise! Anyone think there may be more upside?
              3
              • Price target high 9$
                0
              • bro then send me bit of ur profit
                4
            • Expecting much more down side on a friday sell off, but nah not too bad so far
              0
              • What's do think guy for today?
                0
                • 9
                  2
                • stock guru9 is a far strech with what they just announced!
                  0
                • Cambron Eaton do you think it will continue to go down
                  0
              • Price target 9$
                0